Skip to search formSkip to main contentSkip to account menu

CR 2039

Known as: CR-2039, CR2039 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice
SummaryCR 2039 [4-(1H-tetrazol-5-yl)-N-(4-(1H-tetrazol-5-yl]phenylbenzamide], in doses of 10, 50, and 100mg/kg i.p… 
1998
1998
A potential anti-asthmatic drug, CR 2039, enhances the anticonvulsive activity of some antiepileptic drugs against pentetrazol in mice
1997
1997
New inhalation products containing CR 2039 (Andolast)
1992
1992
CR 2039, a new bis-(1H-tetrazol-5-yl)phenylbenzamide derivative with potential for the topical treatment of asthma.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)